Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart

Psychopharmacology

Volumn 225, Issue 4, 2013, Pages 883-893

  Peiro A M ^a,b   Farre M ^a,b   Roset, P N ^a,b   Carbo M ^a,c   Pujadas, M ^a   Torrens, M ^b,d   Cami J ^c   De La Torre, R ^a,c,e  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d Addiction Unit INAD   (Spain)

^e CIBEROBN   (Spain)

Author keywords

CYP2D6; Ecstasy; Humans; MDMA; Metabolic inhibition; Pharmacokinetics; Pharmacologic effects; Repeated dose

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; EUPHORIA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SYSTOLIC BLOOD PRESSURE; TOXICOKINETICS;

ADULT; AFFECT; BLOOD PRESSURE; BODY TEMPERATURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEART RATE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 84873714355     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2894-7     Document Type: Article

References (41)

1. Camí J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("Ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466
2. Cleary L, Docherty JR (2003) Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur J Pharmacol 476:31-34
3. Crean RD, Davis SA, Von Huben SN, Lay CC, Katner SN, Taffe MA (2006) Effects of (+/-) 3,4-methylenedioxymethamphetamine, (+/-)3,4- methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142:515-525
4. Cuyàs E, Verdejo-García A, Fagundo AB, Khymenets O, Rodríguez J, Cuenca A, de Sola LS, Langohr K, Peña-Casanova J, Torrens M, Martín-Santos R, Farré M, de la Torre R (2011) The influence of genetic and environmental factors among MDMA users in cognitive performance. PLoS One 6(11):e27206
5. De la Torre R, Farré M, Roset P, Hernández-López C, Mas M, Ortuño J et al (2000a) Pharmacology of MDMA in humans. Ann NY Acad Sci 914:225-237
6. De la Torre R, Farré M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000b) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109
7. De la Torre R, Farré M, Mathuna BO, Roset PN, Pizarro N, Segura M et al (2005) MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 61:551-554
8. de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farré M, Pacifici R, Böhm P, Abanades S, Verdejo García A, Langohr K, Zuccaro P, de la Torre R (2008) Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol 22:498-510
9. Farré M, De La Torre R, Mathuna BO, Roset PN, Peiró AM, Torrens M et al (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364-375
10. Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O' Mathuna B et al (2007) Pharmacological interaction between 3,4- methylenedioxymethamphetamine (MDMA, ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954-962
11. Freedman R, Johanson C, Tancer M (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183:248-256
12. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI (2004a) Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated (\'binge\' ingestion) low dose of MDMA. Psychopharmacology (Berl) 173:264-269
13. Green AR, O'Shea E, Colado MI (2004b) A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 500:3-13
14. Greene S, Dargan P, O'connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21:121-124
15. Hammersley R, Ditton J, Smith I, Short E (1999) Patterns of ecstasy use by drug users. Br J Criminol 39:625-647
16. Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J et al (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300:236-244
17. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R et al (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther 90:246-255
18. 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286-294
19. Kollins SH, Rush CR (2002) Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans. Biol Psychiatry 51:143-150
20. Kuypers KP, Wingen M, Samyn N, Limbert N, Ramaekers JG (2007) Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology (Berl) 192:111-119
21. Lamas X, Farré M, Llorente M, Camí J (1994) Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend 35:203-209
22. Lester SJ, Baggott M, Welm S, Schiller N, Jones RT, Foster E et al (2000) Cardiovascular effects of 3,4-methylenedioxymethamphetamine. Ann Intern Med 133:969-973
23. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521
24. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396-404
25. Liechti M, Geyer M, Hell D, Vollenweider F (2001) Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24:240-252
26. Liecthi ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4 methylenedioxymethamphetamine ("Ecstasy") in healthy volunteers. J Psychopharmacol 14:269-274
27. Martín-Santos R, Torrens M, Poudevida S, Langohr K, Cuyás E, Pacifici R, Farré M, Pichini S, de la Torre R (2010) 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study. Addict Biol 15:15-22
28. Mas M, Farré M, la Torre R, Roset PN, Ortuño J, Segura J et al (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145
29. Mills E, Rusyniak D, Sprague J (2004) The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med 82:787-799
30. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ (2011) Pill content, dose and resulting plasma concentrations of 3,4- methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106:1293-1300
31. O'Connor B (1994) Hazards associated with the recreational drug "ecstasy". Br J Hosp Med 52:507-514
32. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926
33. Parrott A (2005) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacology 19:71-83
34. Pizarro N, Ortuño J, Farré M, Hernández-López C, Pujadas M, Llebaria A et al (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165
35. Riley S, James C, Gregory D, Dingle H, Cadger M (2001) Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 96:1035-1047
36. Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65:97-101
37. Verheyden S, Henry J, Curran H (2003) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18:507-517
38. Von Huben SN, Lay CC, Crean RD, Davis SA, Katner SN, Taffe MA (2007) Impact of ambient temperature on hyperthermia induced by (+/-)3,4- methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 32:673-681
39. Walsh SL, Haberny KA, Bigelow GE (2000) Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150:361-373
40. Yang J, Jamei M, Heydari A, de la Torre M, Farré M, Tucker GT, Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849
41. Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R (2011) Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet 50:319-329